Thread Expands Collaboration with Datavant
Thread has announced the launch of a tokenization feature on its research platform that connects clinical trial and real-world data. This advancement, which expands Thread's collaboration with Datavant, leverages Datavant's connectivity tools that enable clients to tokenize, match, and link patient records across de-identified datasets while preserving patient privacy in compliance with regulations.
By engaging these tools to connect clinical trial data with real-world data, biopharmaceutical companies can unlock their studies' full potential by generating a longitudinal view of the patient journey. This solution supports advancing research data access to provide a deeper understanding of patient outcomes.
"Thread's enhanced tokenization feature, backed by Datavant's leading de-identification technology, is a powerful shift in the way real-world data can be integrated into clinical trials. Our customers can now gain and integrate their clinical and real-world data in a few clicks to support their goal of generating additional evidence," said Thread Co-Founder and CEO John Reites in a press release.
"Linking clinical trial data with real-world data can yield enormous benefits for both life sciences researchers and patients, by generating better evidence on treatment safety and efficacy while reducing the burden on trial participants," said Tal Rosenberg, president and general manager, life sciences, ecosystem & public sector at Datavant in a press release. "We're thrilled to enhance our use case by embedding Datavant's technology onto Thread's no-code platform and offering the power of connected clinical trials to a broader customer base."
Reference
THREAD EXPANDS DATAVANT PARTNERSHIP TO LAUNCH FULLY CONFIGURABLE SOLUTION FOR REAL-WORLD DATA LINKAGE. (2023, October 3). Cision PR Newswire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
